Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · IEX Real-Time Price · USD
1.925
-0.005 (-0.26%)
Jul 22, 2024, 10:24 AM EDT - Market open
Tempest Therapeutics Employees
Tempest Therapeutics had 17 employees as of December 31, 2023. The number of employees decreased by 2 or -10.53% compared to the previous year.
Employees
17
Change (1Y)
-2
Growth (1Y)
-10.53%
Revenue / Employee
n/a
Profits / Employee
-$1,750,529
Market Cap
42.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | 17 | 3 | 21.43% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| NeueHealth | 1,252 |
| Fortress Biotech | 186 |
| Co-Diagnostics | 155 |
| Owlet | 76 |
| OncoCyte | 46 |
| Envoy Medical | 34 |
| Movano | 30 |
| Dyadic International | 7 |
TPST News
- 4 weeks ago - What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday? - Benzinga
- 4 weeks ago - Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma - GlobeNewsWire
- 6 weeks ago - Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST) - Business Wire
- 2 months ago - Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting - GlobeNewsWire
- 3 months ago - Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications - GlobeNewsWire
- 4 months ago - Tempest Reports Year End 2023 Financial Results and Provides Business Update - GlobeNewsWire